Anavex Life Sciences Corp. (AVXL): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVXL Stock Price Chart Interactive Chart >
AVXL Price/Volume Stats
| Current price | $10.87 | 52-week high | $15.24 |
| Prev. close | $10.05 | 52-week low | $7.13 |
| Day low | $10.06 | Volume | 1,371,869 |
| Day high | $10.89 | Avg. volume | 1,302,433 |
| 50-day MA | $9.79 | Dividend yield | N/A |
| 200-day MA | $10.18 | Market Cap | 847.45M |
Anavex Life Sciences Corp. (AVXL) Company Bio
Anavex Life Sciences Corporation is engaged in the discovery and development of drugs for the treatment of Alzheimers disease, central nervous system diseases, and pain and various cancers. The company was founded in 2006 and is based in New York, New York.
Latest AVXL News From Around the Web
Below are the latest news stories about ANAVEX LIFE SCIENCES CORP that investors may wish to consider to help them evaluate AVXL as an investment opportunity.
We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's DrugThe FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data. |
3 Biotech Stocks Under $15 Worth a Second Look in 2023Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy. |
Top Picks For 2023: Anavex Life SciencesAnavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett Syndrome. Let's see why it's a favorite for 2023. |
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's WhyThe biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data. |
AVXL Price Returns
| 1-mo | 17.39% |
| 3-mo | -7.72% |
| 6-mo | 0.37% |
| 1-year | -16.90% |
| 3-year | 280.07% |
| 5-year | 304.09% |
| YTD | 17.39% |
| 2022 | -46.60% |
| 2021 | 221.11% |
| 2020 | 108.49% |
| 2019 | 66.03% |
| 2018 | -51.55% |
Loading social stream, please wait...